Ariad Pharmaceuticals, Inc.  

(Public, NASDAQ:ARIA)   Watch this stock  
Find more results forARIA
7.51
-0.28 (-3.59%)
Real-time:   10:36am GMT-4
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.47 - 7.80
52 week 2.15 - 23.00
Open 7.78
Vol / Avg. 1.88M/11.77M
Mkt cap 1,399.31M
P/E     -
Div/yield     -
EPS -1.49
Shares 186.32M
Beta 1.50
Inst. own 65%
Jun 16, 2014
ARIAD Pharmaceuticals, Inc. Annual Shareholder Meeting (Estimated) Add to calendar
May 7, 2014
Q1 2014 ARIAD Pharmaceuticals, Inc. Earnings Release - 9:30am GMT-4 - Add to calendar
May 7, 2014
Q1 2014 ARIAD Pharmaceuticals, Inc. Earnings Conference Call - 8:30am GMT-4 - Add to calendar
Mar 4, 2014
ARIAD Pharmaceuticals, Inc. at Cowen Health Care Conference - Webcast
Feb 26, 2014
ARIAD Pharmaceuticals, Inc. at RBC Capital Markets Healthcare Conference - Webcast
Feb 25, 2014
Q4 2013 ARIAD Pharmaceuticals, Inc. Earnings Release
Feb 25, 2014
Q4 FY 2013 ARIAD Pharmaceuticals, Inc. Earnings Conference Call - Webcast
Feb 12, 2014
ARIAD Pharmaceuticals, Inc. at Leerink Swann Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -887.86% -601.74%
Operating margin -883.61% -600.44%
EBITD margin - -591.36%
Return on average assets -76.50% -99.50%
Return on average equity -135.42% -183.77%
Employees 307 -
CDP Score - -

Address

26 LANDSDOWNE ST
CAMBRIDGE, MA 2139
United States - Map
+1-617-4940400 (Phone)
+1-617-4948144 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD�s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. As of January 11, 2013, additional clinical trials of Iclusig in other cancers were ongoing. As of January 11, 2013, ARIAD also studied AP26113, another molecularly targeted medicine, in certain forms of lung cancer.

Officers and directors

Harvey J. Berger M.D. Chairman of the Board, President, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Edward M. Fitzgerald Chief Financial Officer, Executive Vice President, Treasurer
Age: 58
Bio & Compensation  - Reuters
Raymond T. Keane Esq. Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Age: 54
Bio & Compensation  - Reuters
David L. Berstein Esq. Senior Vice President, Chief Intellectual Property Officer
Age: 61
Bio & Compensation  - Reuters
Daniel M. Bollag Ph.D. Senior Vice President - Regulatory Affairs and Quality
Age: 52
Bio & Compensation  - Reuters
Maria E. Cantor Senior Vice President - Corporate Affairs
Age: 45
Bio & Compensation  - Reuters
Hugh M. Cole Senior Vice President, Chief Business Officer
Bio & Compensation  - Reuters
Pierre F. Dodion M.D. Senior Vice President - Corporate Development and Operations
Age: 58
Bio & Compensation  - Reuters
Martin J. Duvall Senior Vice President - Commercial Operations
Age: 50
Bio & Compensation  - Reuters
Frank G. Haluska M.D., Ph.D. Senior Vice President - Clinical Research and Development and Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters